APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03502330 |
Recruitment Status :
Active, not recruiting
First Posted : April 18, 2018
Last Update Posted : July 26, 2022
|
Sponsor:
Yale University
Collaborators:
Bristol-Myers Squibb
Apexigen, Inc.
Information provided by (Responsible Party):
Yale University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | November 2022 |
Estimated Study Completion Date : | October 2027 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):